Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR Trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502076-23-00

Enrollment

120

Registered

2023-03-01

Start date

2023-08-16

Completion date

Unknown

Last updated

2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteopenia, Osteoporosis

Brief summary

Change in circulating marker of bone resorption (CTX) at 21 weeks.

Detailed description

Bone resorption marker tartrate resistant acid phosphatase (TRAcP) at 21 weeks., Bone formation markers (PINP, osteocalcin, and bone alkaline phosphatase) at 21 weeks.

Interventions

DRUGDASATINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in circulating marker of bone resorption (CTX) at 21 weeks.	—

Secondary

Measure	Time frame
Bone resorption marker tartrate resistant acid phosphatase (TRAcP) at 21 weeks., Bone formation markers (PINP, osteocalcin, and bone alkaline phosphatase) at 21 weeks.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026